• standardized
  • personalized
  • therapeutic
  • cancer vaccines

Immunicum AB (publ), a clinical phase II company, develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of tumor-specific T-cells, are based on many years of research within the area of transplantation immunology.

Immunicum’s main product has been evaluated in a finalized clinical Phase I/II-study in metastatic renal cell carcinoma and is ready for testing in a clinical phase II-trial. The Company is also conducting a clinical Phase I/II-study in primary liver cancer.

 

Om Immunicum

ABOUT IMMUNICUM

Immunicum is a biopharmaceutical company that was founded in 2002 as a spinoff from Sahlgrenska University Hospital, in Gothenburg, Sweden

Teknologi

TECHNOLOGY

Immunicum has three different platforms for the development of cancer immunotherapies

Pipeline

PIPELINE

Immunicum has four ongoing projects, with a strong focus on the ongoing clinical trial in renal cell carcinoma

Investerare & Media

Investors

Press releases, financial reports, calendar, meetings/presentations, etc.

Latest news

Read more

ASCO-dataRead more

Immunicum Located at
Grafiska vägen 2, 412 63, Gothenburg.
Phone: +46 31 41 50 52